2D QSAR of Novel hybrid motifs of 4-nitroimidazole-piperazinyl tagged 1,2,3-triazoles for Anti-cancer Activity against Breast Cancer cell line MCF-7
Abstract
Objective: To develop and validate a two‑dimensional quantitative structure–activity relationship (2D‑QSAR) model for novel 4‑nitroimidazole‑piperazinyl tagged 1,2,3‑triazole derivatives and to identify key physicochemical descriptors governing their anticancer activity against the human breast cancer cell line MCF‑7.
Results and Discussion: Several statistically acceptable QSAR models were obtained; among them, Model 1, incorporating Molar Refractivity, partition coefficient, Henry’s law constant, mass, and molecular weight, showed the most favorable balance of correlation and error (r ≈ 0.45, r² ≈ 0.20, standard deviation ≈ 0.50) with a single outlier. Descriptor analysis indicated that Molar Refractivity is positively correlated with MCF‑7 inhibitory activity, suggesting that bulkier or more polarizable substituents enhance cytotoxic potency, while the partition coefficient term supports a beneficial role of less polar, more lipophilic groups. The results demonstrate that the thermodynamic and electronic nature of substituents strongly influences activity and that even a moderate‑fit 2D‑QSAR model can serve as a useful predictive tool for prioritizing new analogues.
Conclusion: The 2D‑QSAR study established that MCF‑7 cell inhibitory activity of 4‑nitroimidazole‑piperazinyl tagged 1,2,3‑triazole derivatives is primarily governed by Molar Refractivity, lipophilicity‑related parameters, and other thermodynamic–electronic descriptors of the substituents. The optimized Model 1 provides a rational basis for designing new hybrids with higher molecular refractivity and appropriately tuned hydrophobic and electronic profiles to achieve improved anticancer potency, and the proposed QSAR framework can be applied to further scaffold optimization against breast cancer targets.
Keywords: Quantitative Structure Activity Relationship (QSAR), Anti-Cancer,imidazole, ChemDraw, MCF-7 Cell.
Keywords:
Quantitative Structure Activity Relationship (QSAR), Anti-Cancer, imidazole, ChemDraw, MCF-7 CellDOI
https://doi.org/10.22270/jddt.v16i4.7662References
1. Giere RN. Science without laws. University of Chicago press; 1999.
2. Perspectives in Biology and Medicine, volume 62, number 4 (autumn 2019): 778-786. https://doi.org/10.1353/pbm.2019.0046 PMid:31761807
3. Nagarajan D, McArdle SE. Immune landscape of breast cancers. Biomedicines. 2018 Feb 11;6(1):20. https://doi.org/10.3390/biomedicines6010020 PMid:29439457 PMCid:PMC5874677
4. Makhoul I, Atiq M, Alwbari A, Kieber-Emmons T. Breast cancer immunotherapy: an update. Breast cancer: basic and clinical research. 2018 May 30;12:1178223418774802. https://doi.org/10.1177/1178223418774802 PMid:29899661 PMCid:PMC5985550
5. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of clinical oncology. 2008 Mar 10;26(8):1275-81. https://doi.org/10.1200/JCO.2007.14.4147 PMid:18250347
6. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of clinical investigation. 2011 Jul 1;121(7):2750-67. https://doi.org/10.1172/JCI45014 PMid:21633166 PMCid:PMC3127435
7. Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. Journal of immunology research. 2014;2014(1):149185. https://doi.org/10.1155/2014/149185 PMid:24901008 PMCid:PMC4036716
8. Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, Safari E, Farahmand L. Breast cancer: Biology, biomarkers, and treatments. International immunopharmacology. 2020 Jul 1;84:106535 https://doi.org/10.1016/j.intimp.2020.106535 PMid:32361569
9. Erlay J. GLOBOCAN 2012 v1. 0, cancer incidence and mortality worldwide: IARC CancerBase No. 11 (Internet). Int Agency Res Cancer. 2013;42:124.
10. Youlden DR, Cramb SM, Yip CH, Baade PD. Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer biology & medicine. 2014 Jun 1;11(2):101-15.
11. Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, Sarkar S. Drug resistance in cancer: an overview. Cancers. 2014 Sep 5;6(3):1769-92. https://doi.org/10.3390/cancers6031769 PMid:25198391 PMCid:PMC4190567
12. Jorgensen WL. The many roles of computation in drug discovery. Science. 2004 Mar 19;303(5665):1813-8. https://doi.org/10.1126/science.1096361 PMid:15031495
13. Márquez Martín A, De La Puerta Vázquez R, Fernández-Arche A, Ruiz-Gutiérrez V. Supressive effect of maslinic acid from pomace olive oil on oxidative stress and cytokine production in stimulated murine macrophages. Free radical research. 2006 Jan 1;40(3):295-302. https://doi.org/10.1080/10715760500467935 PMid:16484046
14. Kapoor S. Maslinic acid and its in vitro antineoplastic effects. Nat Prod Res. 2013;27(23):2210-2211. https://doi.org/10.1080/14786419.2013.819506 PMid:24004213
15. Verma J, Khedkar VM, Coutinho EC. 3D-QSAR in drug design-a review. Current topics in medicinal chemistry. 2010 Jan 1;10(1):95-115. https://doi.org/10.2174/156802610790232260 PMid:19929826
16. Cherkasov A, Muratov EN, Fourches D, Varnek A, Baskin II, Cronin M, Dearden J, Gramatica P, Martin YC, Todeschini R, Consonni V. QSAR modeling: where have you been? Where are you going to?. Journal of medicinal chemistry. 2014 Jun 26;57(12):4977-5010. https://doi.org/10.1021/jm4004285 PMid:24351051 PMCid:PMC4074254
17. Ling J, Kumar R. Crosstalk between NFkB and glucocorticoid signaling: a potential target of breast cancer therapy. Cancer letters. 2012 Sep 28;322(2):119-26. https://doi.org/10.1016/j.canlet.2012.02.033 PMid:22433713
18. Alam S, Khan F. 3D-QSAR studies on Maslinic acid analogs for Anticancer activity against Breast Cancer cell line MCF-7. Scientific reports. 2017 Jul 20;7(1):6019. https://doi.org/10.1038/s41598-017-06131-0 PMid:28729623 PMCid:PMC5519539
19. Fuentes N, Silveyra P. Estrogen receptor signaling mechanisms. Adv Protein Chem Struct Biol. 2019;116:135-170. https://doi.org/10.1016/bs.apcsb.2019.01.001 PMid:31036290 PMCid:PMC6533072
20. Hewitt SC, Korach KS. Estrogen receptors: new directions in the new millennium. Endocr Rev. 2018. https://doi.org/10.1210/er.2018-00087 PMid:29901737 PMCid:PMC6173474
21. Folkerd EJ, Dowsett M. Influence of sex hormones on cancer progression. J Clin Oncol. 2010;28:4038-4044. https://doi.org/10.1200/JCO.2009.27.4290 PMid:20644089
22. Zheng B, Zhu Y, Wang HY, Chen L. Gender disparity in hepatocellular carcinoma (HCC): multiple underlying mechanisms. Sci China Life Sci. 2017;60:575-584. https://doi.org/10.1007/s11427-016-9043-9 PMid:28547581
23. Wang LNG, Qian Y, Yang Q, Tan H, Drummer C, Sun Y, et al. A comprehensive data mining study shows that most nuclear receptors act as newly proposed homeostasis-associated molecular pattern receptors. J Hematol Oncol. 2017;10:168. https://doi.org/10.1186/s13045-017-0526-8 PMid:29065888 PMCid:PMC5655880
24. Chen P, Li B, Ou-Yang L. Role of estrogen receptors in health and disease. Front Endocrinol (Lausanne). 2022;13. https://doi.org/10.3389/fendo.2022.839005 PMid:36060947 PMCid:PMC9433670
25. Tang ZR, Zhang R, Lian ZX, Deng SL, Yu K. Estrogen receptor expression and function in female reproductive disease. Cells. 2019;8:1123-1138. https://doi.org/10.3390/cells8101123 PMid:31546660 PMCid:PMC6830311
26. Eyster KM. The estrogen receptors: an overview from different perspectives. Methods Mol Biol. 2016;1366. https://doi.org/10.1007/978-1-4939-3127-9
27. Huang B, Omoto Y, Iwase H, Yamashita H, Toyama T, Coombes RC, et al. Differential expression of estrogen receptor α, β1 and β2 in lobular and ductal breast cancer. Proc Natl Acad Sci U S A. 2014;111:1933-1938. https://doi.org/10.1073/pnas.1323719111 PMid:24449868 PMCid:PMC3918808
28. Johnston SR, Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer. 2003;3:821-831. https://doi.org/10.1038/nrc1211 PMid:14668813
29. Anderson WF, Chatterjee N, Brawley OW, Ershler WB. Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat. 2002;76:27-36. https://doi.org/10.1023/A:1020299707510 PMid:12408373
30. Shtaiwi A, et al. Computational investigations of the binding mechanism of novel benzophenone imine inhibitors for the treatment of breast cancer. RSC Adv. 2019;9:35401-35416. https://doi.org/10.1039/C9RA04759J PMid:35541022 PMCid:PMC9082406
31. Lykkesfeldt AE, Sørensen EO. Effect of estrogen and antiestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and a tamoxifen-resistant variant subline AL-1. Acta Oncol. 1992;31:131-138. https://doi.org/10.3109/02841869209088892 PMid:1622627
32. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev. 1999;20:358-417. https://doi.org/10.1210/edrv.20.3.0370 PMid:10368776
33. Treeck OJ, Brucker I, Lattrich C, Horn F, Goerse R, Ortmann O, et al. Effects of exon-deleted estrogen receptor β transcript variants on growth, apoptosis and gene expression of human breast cancer cell lines. Breast Cancer Res Treat. 2008;110:507-520. https://doi.org/10.1007/s10549-007-9749-7 PMid:17876701
34. Cotrim CFV, Doria ML, Lindberg K, Gustafsson JÅ, Amado F, et al. Estrogen receptor beta growth inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells. Oncogene. 2013;32:2390-2402. https://doi.org/10.1038/onc.2012.261 PMid:22751110
35. Speirs V, Malone C, Walton DS, Kerin MJ, Atkin SL. Increased expression of estrogen receptor β mRNA in tamoxifen-resistant breast cancer patients. Cancer Res. 1999;59:5421-5424.
36. Markey GC, Roche PC, Diggin P, Hill AD, McDermott EW, O'Higgins NJ, et al. Estrogen receptor-β mRNA is associated with adverse outcome in patients with breast cancer. Tumor Biol. 2009;30:171-175. https://doi.org/10.1159/000236409 PMid:19738412
37. Marengo SR, Chung LW. An orthotopic model for the study of growth factors in the ventral prostate of the rat: effects of epidermal growth factor and basic fibroblast growth factor. J Androl. 1994;15:277-286. https://doi.org/10.1002/j.1939-4640.1994.tb00450.x
38. Bonkhoff H. Estrogen receptor signaling in prostate cancer: implications for carcinogenesis and tumor progression. Prostate. 2018;78:2-10. https://doi.org/10.1002/pros.23446 PMid:29094395
39. Iyer JK, McCabe KM, Kaul A, Payton ME, Kaul R. Estrogen receptor expression in chronic hepatitis C and hepatocellular carcinoma pathogenesis. World J Gastroenterol. 2017;23:6802-6816. https://doi.org/10.3748/wjg.v23.i37.6802 PMid:29085224 PMCid:PMC5645614
40. Hou JX, Jiang R, Wang Y, Chen C, Deng L, et al. Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3. Hepatology. 2013;57:678-685. https://doi.org/10.1002/hep.25980 PMid:22821478
41. Chen JJ, Tang Y, Huang SF, Ai JG, Wang HX, Zhang LP. HBx protein-induced upregulation of microRNA-221 promotes aberrant proliferation in HBV-related hepatocellular carcinoma by targeting estrogen receptor-α. Oncol Rep. 2015;33:792-798. https://doi.org/10.3892/or.2014.3647 PMid:25483016
42. Yang WL, Yang Y, Xu L, Zheng W, Wu Y, et al. Estrogen represses hepatocellular carcinoma growth via inhibiting alternative activation of tumor-associated macrophages. J Biol Chem. 2012;287:40140-40149. https://doi.org/10.1074/jbc.M112.348763 PMid:22908233 PMCid:PMC3504728
43. Lin VB, Yeh YL, Tu CC, Ho TJ, Lai TY, et al. Activation of estrogen receptors with E2 downregulates peroxisome proliferator-activated receptor-γ in hepatocellular carcinoma. Oncol Rep. 2013;30:3027-3031. https://doi.org/10.3892/or.2013.2793 PMid:24126791
44. Arora P, Arora V, Lamba H, Wadhwa D. Importance of heterocyclic chemistry: a review. Int J Pharm Sci Res. 2012;3:2947-2954.
45. Zadsirjan MM, Vessally H. Prescribed drugs containing nitrogen heterocycles. RSC Adv. 2020;10:44247-44311. https://doi.org/10.1039/D0RA09198G PMid:35557843 PMCid:PMC9092475
46. Hernani PMTF, Silva AL. Synthesis of 2,3,5-substituted pyrrole derivatives. Tetrahedron Lett. 2002;43:4491-4493. https://doi.org/10.1016/S0040-4039(02)00810-9
47. Daidone G, Bivona M, Schillari D. Salicylanilide and its heterocyclic analogs: a comparative study of their antimicrobial activity. Pharmazie. 1990;45:441-442.
48. Almerico AM, Diana P, Barraja P, Dattolo G, Mingoia F, Loi AG, et al. Glycosidopyrroles. Part 3: Effect of benzocondensation on acyclic derivatives: 1-(2-hydroxyethoxy)methylindoles as potential antiviral agents. Il Farmaco. 1998;53:33-40. https://doi.org/10.1016/S0014-827X(97)00002-5 PMid:9543724
49. Schaefer EJ, McNamara JR, Tayler T, Daly JA, Gleason JL, Seman LJ, et al. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am J Cardiol. 2004;93:31-39. https://doi.org/10.1016/j.amjcard.2003.09.008 PMid:14697462
50. Yang D, Bao A, Wei W, Tian L, Huang B, Wang H. Copper-catalyzed domino synthesis of nitrogen heterocycle-fused benzoimidazole and 1,2,4-benzothiadiazine 1,1-dioxide derivatives. ACS Comb Sci. 2015;17:113-119. https://doi.org/10.1021/co500125n PMid:25549532
51. Wermuth CG. The Practice of Medicinal Chemistry. Amsterdam: Elsevier; 2004.
52. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod. 2003;66:1022-1037. https://doi.org/10.1021/np030096l PMid:12880330
53. Cragg GM, Newman DJ, Snader KM. Natural products in drug discovery and development. J Nat Prod. 1997;60:52-60. https://doi.org/10.1021/np9604893 PMid:9014353
54. Nepali K, Sharma S, Sharma M, Bedi PM, Dhar KL. Rational approaches, design strategies, structure-activity relationship and mechanistic insights for anticancer hybrids. Eur J Med Chem. 2014;77:422-487. https://doi.org/10.1016/j.ejmech.2014.03.018 PMid:24685980
55. Sandhu S, Bansal Y, Silakari O, Bansal G. Coumarin hybrids as novel therapeutic agents. Bioorg Med Chem. 2014;22:3806-3814. https://doi.org/10.1016/j.bmc.2014.05.032 PMid:24934993
56. Basanagouda M, Veeresh B, Barigidad N, Laxmeshwar S, Devaru S, Venkatesh N. Synthesis and structure-activity relationship of iodinated 4-aryloxymethylcoumarins as potential anticancer and antimycobacterial agents. Eur J Med Chem. 2014;74:225-233. https://doi.org/10.1016/j.ejmech.2013.12.061 PMid:24463645
57. Riveiro ME, Astudillo AM, Vazquez R, Gomez N, Facorro G, Piehl L, et al. Structural insights into hydroxycoumarin-induced apoptosis in U-937 cells. Bioorg Med Chem. 2008;16:2665-2675. https://doi.org/10.1016/j.bmc.2007.11.038 PMid:18060791
58. Erlanson DA, McDowell RS, O'Brien T. Fragment-based drug discovery. J Med Chem. 2004;47:3463-3482. https://doi.org/10.1021/jm040031v PMid:15214773
59. Sun YZ, Fura A, Zhu M, Hanson RL, Roongta V, Humphreys WG. Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery. J Med Chem. 2004;47:4339-4351. https://doi.org/10.1021/jm040066v PMid:15317447
60. Lima LM, Barreiro EJ. Bioisosterism: a useful strategy for molecular modification and drug design. Curr Med Chem. 2005;12:23-49. https://doi.org/10.2174/0929867053363540 PMid:15638729
61. Wermuth CG. Selective optimization of side activities: another way for drug discovery. J Med Chem. 2004;47:1303-1314. https://doi.org/10.1021/jm030480f PMid:14998318
62. Chin CM, Ferreira EI. O processo de latenciação no planejamento de fármacos. Quim Nova. 1999;22:75-81. https://doi.org/10.1590/S0100-40421999000100014
63. Kolb HC, Finn MG, Sharpless KB. Click chemistry: diverse chemical function from a few good reactions. Angew Chem Int Ed. 2001;40:2004-2021. https://doi.org/10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5 PMid:11433435
64. Agalave SG, Maujan SR, Pore VS. Click chemistry: 1,2,3-triazoles as pharmacophores. Chem Asian J. 2011;6:2696-2718. https://doi.org/10.1002/asia.201100432 PMid:21954075
65. Kushwaha K, Kaushik N, Jain S. Design and synthesis of novel 2H-chromen-2-one derivatives bearing 1,2,3-triazole moiety as lead antimicrobials. Bioorg Med Chem Lett. 2014;24:1795-1801. https://doi.org/10.1016/j.bmcl.2014.02.027 PMid:24594353
66. Behbehani H, Ibrahim HM, Makhseed S, Mahmoud H. Applications of 2-arylhydrazononitriles in synthesis: preparation of new indole containing 1,2,3-triazole, pyrazole and pyrazolo[1,5-a]pyrimidine derivatives and evaluation of their antimicrobial activities. Eur J Med Chem. 2011;46:1813-1820. https://doi.org/10.1016/j.ejmech.2011.02.040 PMid:21397366
67. Majeed R, Saeed P, Chinthakindi PK, Khan I, Dangroo NA, Thota N, et al. Synthesis of 3-O-propargylated betulinic acid and its 1,2,3-triazoles as potential apoptotic agents. Eur J Med Chem. 2013;63:782-792. https://doi.org/10.1016/j.ejmech.2013.03.028 PMid:23584541
68. Elamari H, Sapi J, Chabot GG, Quentin L, Scherman D, Girard C. Synthesis and in vitro evaluation of mono- and bis-1,2,3-triazole derivatives of bis-alkynes as potential anticancer agents. Eur J Med Chem. 2013;60:360-364. https://doi.org/10.1016/j.ejmech.2012.12.025 PMid:23314049
69. Kolb HC, Sharpless KB. The growing impact of click chemistry on drug discovery. Drug Discov Today. 2003;8:1128-1137. https://doi.org/10.1016/S1359-6446(03)02933-7 PMid:14678739
70. Zhang W, Li Z, Zhou M, Wu F, Hou X, Luo H, et al. Synthesis and biological evaluation of 4-(1,2,3-triazol-1-yl)coumarin derivatives as potential antitumor agents. Bioorg Med Chem. 2014;24:799-807. https://doi.org/10.1016/j.bmcl.2013.12.095 PMid:24418772
71. Al-Masoudi NA, Pieroni M, Pannecouque C. Nitroimidazoles. Part 7: Synthesis and anti-HIV activity of new 4-nitroimidazole derivatives. Z Naturforsch B. 2012;67:835-842. https://doi.org/10.5560/znb.2012-0122
72. Al-Soud YA, Al-Masoudi NA, Amajaour HA, De Clercq E. Nitroimidazoles. Part 3: Synthesis and anti-HIV activity of new N-alkyl 4-nitroimidazoles bearing benzothiazole and benzoxazole backbones. Z Naturforsch B. 2007;62:523-528. https://doi.org/10.1515/znb-2007-0406
73. Abuteen A, Dietz FZ, Mohammad I, Smith MB, Zhu Q. Synthesis of a 4-nitroimidazole indocyanine dye conjugate and imaging of tumor hypoxia in BALB/c tumor-bearing female mice. Dyes Pigments. 2015;126:251-260. https://doi.org/10.1016/j.dyepig.2015.12.010
74. Varshney V, Misra N, Shukla PK, Sahu DP. Synthesis of nitroimidazole derived oxazolidinones as antibacterial agents. Eur J Med Chem. 2010;45:661-666. https://doi.org/10.1016/j.ejmech.2009.11.009 PMid:19942324
75. Al-Qawasmeh RA, Hasan M, Nedunuri V, Peralta R, Wright J, Lee Y, et al. Potent antimicrobial activity of 3-(4,5-diaryl-1H-imidazol-2-yl)-1H-indole derivatives against methicillin-resistant Staphylococcus aureus. Bioorg Med Chem Lett. 2010;20:3518-3520. https://doi.org/10.1016/j.bmcl.2010.04.137 PMid:20483613
76. Saber SO, Al-Qawasmeh RA, Abu-Qatouseh L, Shtaiwi A, Khanfar MA, Al-Soud YA. Novel hybrid motifs of 4-nitroimidazole-piperazinyl tagged 1, 2, 3-triazoles: Synthesis, crystal structure, anticancer evaluations, and molecular docking study. Heliyon. 2023; 9 (9). https://doi.org/10.1016/j.heliyon.2023.e19327 PMid:37681149 PMCid:PMC10480608
77. Singh AK, Patel J, Jain N, Singour PK. QSAR studies of 2-phenoxyacetamide analogues, a novel class of potent and selective monoamine oxidase inhibitors. Current Research in Pharmaceutical Sciences. 2017:109-16. https://doi.org/10.24092/CRPS.2017.070402
Published
Abstract Display: 31 
PDF Downloads: 14 PDF Downloads: 6 How to Cite
Issue
Section
Copyright (c) 2026 Pranay Raikwar , Arun Kumar Rai , Shabnam Yadav , Nitin Singh Rajput , Shivraj Pandey , Megha Mishra , Pradeep Kumar Singour
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.